Skip to main content
Access Resources

MJFF Publications

1761 - 1770 of 7540 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.13415
    Citation Count: 1
  • RESTRICTED
    Title: An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol
    Journal Name: Pilot and Feasibility Studies
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40814-022-00988-3
    Citation Count: 5
  • RESTRICTED
    Title: Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-021-00317-5
    Citation Count: 4
  • RESTRICTED
    Title: GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28932
    Citation Count: 43
  • RESTRICTED
    Title: Transition and Sustainability of an Online Care Model for People With Parkinson's Disease in Response to the COVID-19 Pandemic
    Journal Name: Frontiers in Public Health
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fpubh.2021.772805
    Citation Count: 4
  • RESTRICTED
    Title: 4R-cembranoid protects neuronal cells from oxygen–glucose deprivation by modulating microglial cell activation
    Journal Name: Brain Research Bulletin
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.brainresbull.2021.12.007
    Citation Count: 5
  • RESTRICTED
    Title: A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105612
    Citation Count: 1
  • RESTRICTED
    Title: Adjunctive Therapies in Parkinson Disease—Have We Made Meaningful Progress?
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2021.4140
    Best OA location URL:
    Citation Count: 1
  • RESTRICTED
    Title: Association of Essential Tremor With Novel Risk Loci
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2021.4781
    Citation Count: 17
  • RESTRICTED
    Title: Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
    Journal Name: BMJ Open
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1136/bmjopen-2021-052032
    Citation Count: 1
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.